The Protein Arginine Deiminases (PADs) hydrolyze arginine residues to form citrulline.  This post-translational modification is upregulated in numerous cancers and autoimmune disorders including RA, lupus, and Alzheimer’s disease.  While these enzymes are important regulators of gene transcription, the full spectrum of biological activities is relatively underexplored. <br/>Herein, I will discuss our efforts to develop next generation inhibitors targeting the PADs, focusing on our success in developing inhibitors with improved potency, selectivity, and cellular and <i>in vivo </i>activity.  These next generation compounds hold therapeutic promise as potential inhibitors of PAD activity.    <br/>

Chemical probes targeting the protein arginine deiminases

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.